{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:41Z","timestamp":1787027021124,"version":"build-2736575974"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Novel oral anticoagulants (NOACs) have been recommended by guidelines as the first-line drugs for preventing cardiogenic stroke. We aimed to provide an overview of the prescription trends and dosing appropriateness of NOACs in China.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    We conducted a retrospective analysis of NOAC prescriptions using the Hospital Prescription Analysis Cooperation Project data from 2016 to 2022. Various patient features, such as gender, age, city, year, source, department visited, original diagnosis, dosing, cost, and insurance type, were collected and analyzed to examine the trends and dosing appropriateness of NOAC usage in ischemic stroke patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    62,014 NOAC prescriptions were analyzed, including 16,602 for dabigatran, 45,253 for rivaroxaban, and 159 for apixaban. 85.14% of the patients were aged 65 or above, and tertiary hospitals accounted for 95.97% of NOAC prescriptions. NOAC prescriptions rose from 1828 in 2016 to 13,998 in 2021 but dropped to 13,166 in 2022. The percentage of annual prescriptions for NOACs among stroke patients has increased from 0.05% in 2016 to 0.37% in 2022. Total drug cost increased from \u00a5704541.18 in 2016 to \u00a54128648.44 in 2021, then decreased to \u00a51680109.14 in 2022. Prescriptions were divided into 48,321 appropriate and 11,262 inappropriate dosing groups, showing significant differences in medications, age, year, city type, hospital level, source, insurance type, and department visited (all\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001). The median drug cost for inappropriate dosing was higher than for appropriate dosing (\u00a555.20 VS \u00a583.80). The top comorbidities in ischemic stroke patients were atrial fibrillation (35.30%), hypertension (32.75%), and coronary heart disease (16.48%).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    The application of NOACs in the Chinese population is increasing. Our findings highlight the frequent deviation from labeled dosing of NOACs in clinical practice. Continued efforts are necessary to promote the appropriate use of NOACs according to the standard dosage in the drug insert.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2024.1304139","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T01:01:54Z","timestamp":1710205314000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The Prescription trends and dosing appropriateness analysis of novel oral anticoagulants in ischemic stroke patients: a retrospective study of 9 cities in China"],"prefix":"10.3389","volume":"15","author":[{"given":"Mingfen","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1055\/s-0042-1744543","article-title":"Rivaroxaban underdose for atrial fibrillation with stable coronary disease: the AFIRE trial findings","volume":"122","author":"Arashi","year":"2022","journal-title":"Thromb. Haemost."},{"key":"B2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1161\/STROKEAHA.117.018773","article-title":"Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in asian patients with atrial fibrillation","volume":"48","author":"Cha","year":"2017","journal-title":"Stroke"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1016\/j.hrthm.2020.07.022","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation","volume":"17","author":"Chan","year":"2020","journal-title":"Heart Rhythm"},{"key":"B5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3760\/cma.j.cn114798-20201210-01241","article-title":"Guideline for rational medication of atrial fibrillation in primary care","volume":"20","year":"2021","journal-title":"Chin. J. Gen. Pract."},{"key":"B6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1161\/STROKEAHA.118.023093","article-title":"Outcomes after use of standard- and low-dose non-vitamin K oral anticoagulants in asian patients with atrial fibrillation","volume":"50","author":"Cho","year":"2019","journal-title":"Stroke"},{"key":"B7","volume-title":"Notice of the Issuance of national basic medical insurance, work-related injury insurance and Maternity Insurance Drug List","year":"2017"},{"key":"B8","volume-title":"Notice of the Issuance of national basic medical insurance, work-related injury insurance and Maternity Insurance Drug List","year":"2020"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"20","year":"2021","journal-title":"Lancet Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1017\/cjn.2021.127","article-title":"Canadian stroke best practice recommendations: secondary prevention of stroke update 2020","volume":"49","author":"Gladstone","year":"2022","journal-title":"Can. J. Neurol. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.122.062752","article-title":"Direct oral anticoagulants versus warfarin across the spectrum of kidney function: patient-level network meta-analyses from COMBINE AF","volume":"147","author":"Harrington","year":"2023","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1161\/CIRCRESAHA.116.308407","article-title":"Cardioembolic stroke","volume":"120","author":"Kamel","year":"2017","journal-title":"Circ. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American heart association\/American stroke association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"B15","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1161\/STROKEAHA.119.028030","article-title":"Oral anticoagulation in asian patients with atrial fibrillation and a history of intracranial hemorrhage","volume":"51","author":"Lee","year":"2020","journal-title":"Stroke"},{"key":"B16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/ehjcvp\/pvab004","article-title":"Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation","volume":"7","author":"Lee","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/03007995.2021.1885365","article-title":"Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation and valvular heart disease","volume":"37","author":"Li","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"B18","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3969\/j.issn.1673-5765.2023.08.009","article-title":"Guidelines for clinical management of cerebrovascular diseases (second edition) (Excerpt)\u2014\u2014chapter four clinical management of ischaemic cerebrovascular diseases","volume":"18","author":"Liping","year":"2023","journal-title":"Chin. J. Stroke"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1177\/17474930221090347","article-title":"Japan stroke society guideline 2021 for the treatment of stroke","volume":"17","author":"Miyamoto","year":"2022","journal-title":"Int. J. Stroke."},{"key":"B20","volume-title":"National essential medicines list (2018 edition)","year":"2018"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1161\/CIRCULATIONAHA.117.031457","article-title":"Periprocedural outcomes of direct oral anticoagulants versus warfarin in nonvalvular atrial fibrillation","volume":"138","author":"Nazha","year":"2018","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e2317156","DOI":"10.1001\/jamanetworkopen.2023.17156","article-title":"Analysis of oral anticoagulant dosing and adherence to therapy among patients with nonvalvular atrial fibrillation","volume":"6","author":"Rymer","year":"2023","journal-title":"JAMA Netw. Open."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Heart J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1007\/s00415-020-09795-3","article-title":"Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation","volume":"267","author":"Stoll","year":"2020","journal-title":"J. Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e206424","DOI":"10.1001\/jamanetworkopen.2020.6424","article-title":"Association of ischemic stroke, major bleeding, and other adverse events with warfarin use vs non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation with a history of intracranial hemorrhage","volume":"3","author":"Tsai","year":"2020","journal-title":"JAMA Netw. Open."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","article-title":"Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction","volume":"69","author":"Yao","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/STROKEAHA.118.022249","article-title":"Time trends in atrial fibrillation-associated stroke and premorbid anticoagulation: population-based study and systematic review","volume":"50","author":"Yiin","year":"2019","journal-title":"Stroke"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e014177","DOI":"10.1161\/JAHA.119.014177","article-title":"Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with atrial fibrillation","volume":"9","author":"Yu","year":"2020","journal-title":"J. Am. Heart Assoc."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1304139\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T01:02:07Z","timestamp":1710205327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1304139\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":31,"alternative-id":["10.3389\/fphar.2024.1304139"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1304139","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"article-number":"1304139"}}